An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus

Completed · Phase 3

Conditions studied: Diabetes Mellitus, Type 2

In brief

This protocol is designed to evaluate the metabolic effects of adding exenatide, rosiglitazone, or both to an existing regimen of metformin in subjects with inadequate glycemic control.

Key facts

Study ID

NCT00135330

Run by

AstraZeneca

People needed

137

Starts

2005-10-01

Expected to finish

2008-07-01

Last updated by the study team

2015-04-07

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HbA1c of 6.8% to 10.0%, inclusive.
• Body mass index (BMI) of 25 kg/m\^2 to 40 kg/m\^2, inclusive.

You may not qualify if…

• Have participated in this study previously, or have received exenatide, pramlintide acetate, GLP-1 analogs, or dipeptidyl peptidase-IV (DPP-IV) inhibitors
• Have participated in an interventional, medical, surgical, or pharmaceutical study (a study in which an experimental, drug, medical, or surgical treatment was given) within 30 days of study start. This criterion includes drugs that have not received regulatory approval for any indication at the time of study start.
• Treated with any of the following medications:
• Thiazolidinedione within 5 months of screening;
• Sulfonylurea within 3 months of screening;
• Metformin/sulfonylurea combination therapy within 3 months of screening;
• Alpha-glucosidase inhibitor within 3 months of screening;
• Meglitinide within 3 months of screening;
• Insulin for more than 1 week within the 3 months prior to screening.
• Symlin (pramlintide acetate) injection or Byetta (exenatide) injection at any time
• Chronic (more than 2 weeks) or recent (within 4 weeks of study start) use of a drug that directly affects gastrointestinal motility
• Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within the 4 weeks immediately preceding study start
• Regular use of a medication with addictive potential such as an opiate, narcotic, or tranquilizer
• Systemic antineoplastic agent
• Systemic transplantation medication
• Drugs for weight loss, including over-the-counter medications, within the 4 months prior to study start

Where it is running

• Research Site — Phoenix, Arizona, United States
• Research Site — San Francisco, California, United States
• Research Site — Jacksonville, Florida, United States
• Research Site — Orlando, Florida, United States
• Research Site — Atlanta, Georgia, United States
• Research Site — Honolulu, Hawaii, United States
• Research Site — Indianapolis, Indiana, United States
• Research Site — Boston, Massachusetts, United States
• Research Site — Pittsfield, Massachusetts, United States
• Research Site — Minneapolis, Minnesota, United States
• Research Site — Rochester, Minnesota, United States
• Research Site — Syracuse, New York, United States
• Research Site — The Bronx, New York, United States
• Research Site — Cincinnati, Ohio, United States
• Research Site — League City, Texas, United States
• Research Site — New Braunfels, Texas, United States
• Research Site — San Antonio, Texas, United States
• Research Site — Renton, Washington, United States
• Research Site — Spokane, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.